Bio-Techne Corp at UBS Genomics 2.0 and MedTech Innovations Summit Transcript

Aug 17, 2023 / 05:00PM GMT
Elizabeth Cristina Mari Garcia - UBS Investment Bank, Research Division - US Life Science Analyst

Good morning, and welcome. Liza Garcia, the UBS Life Science Tools and Diagnostics analyst. I'm joined today by my co-coverage John Sourbeer as well as Jim Hippel, the CFO of Bio-Techne and David Clair, the IR. Well, thank you guys so much for making the trip out.

James T. Hippel - Bio-Techne Corporation - Executive VP of Finance & CFO

Thanks very much.

Questions and Answers:

Elizabeth Cristina Mari Garcia - UBS Investment Bank, Research Division - US Life Science Analyst

Really appreciate it. Let's just start the discussion. Let's maybe you get high level, Jim and background with the earnings, obviously you just reported the end of your fiscal 2023. Can you just walk through the variables that you're monitoring and thinking about as you're thinking about how fiscal 2024 can maybe shake out and the growth outlook, particularly maybe thinking also about the second half, obviously, interesting time?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot